Evoke Pharma IncNASDAQ:EVOKNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.4580
- TODAY'S CHANGE (%)0.0220 (5.0459%)
- Bid / Lots0.4200/ 4
- Ask / Lots0.4800/ 1
- Open / Previous Close0.4610 / 0.4360
- Day Range
- 52 Week Range
- Volume8,747
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | EVOK |
|---|---|---|
| 09:32 ET | 190 | 0.461 |
| 09:41 ET | 600 | 0.4799 |
| 09:57 ET | 200 | 0.48 |
| 10:15 ET | 199 | 0.4799 |
| 10:28 ET | 135 | 0.4672 |
| 10:33 ET | 115 | 0.4736 |
| 11:04 ET | 100 | 0.475 |
| 11:26 ET | 100 | 0.475 |
| 12:23 ET | 717 | 0.475 |
| 01:32 ET | 931 | 0.4672 |
| 02:38 ET | 100 | 0.437 |
| 03:34 ET | 1962 | 0.48 |
| 03:59 ET | 2437 | 0.458 |
Apr 17, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Evoke Pharma Inc | 3.9M | -0.2x | --- |
Procyon Corp | 1.6M | -5.1x | --- |
DMK Pharmaceuticals Corp | 353.6K | 0.0x | --- |
China Pharma Holdings Inc | 4.5M | -0.3x | --- |
Panacea Life Sciences Holdings Inc | 3.4M | -0.4x | --- |
Akanda Corp | 1.2M | 0.0x | --- |
Company Information
Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. The Company operates through the development and commercialization of pharmaceutical products. It is developing its product, Gimoti (metoclopramide) nasal spray, the first and only nasally administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. It developed Gimoti, a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a novel formulation of metoclopramide offering systemic delivery by nasal spray administration. It has developed the nasal formulation of metoclopramide to provide its targeted patient population with acute or recurrent symptoms of diabetic gastroparesis.
Contact Information
- Headquarters
- 420 Stevens Avenue, Suite 370SOLANA BEACH, CA, United States 92075
- Phone
- 858-345-1494
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Cam Garner
- President, Chief Executive Officer, Treasurer, Secretary, Director
- Matthew D'Onofrio
- Chief Medical Officer
- Marilyn Carlson
- Independent Director
- Todd Brady
- Independent Director
- Malcolm Hill
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.9M |
|---|---|
Revenue (TTM) | $5.2M |
Shares Outstanding | 8.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.36 |
EPS | $-2.33 |
Book Value | $-0.77 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | 0.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -143.44% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
